Patient-reported Outcomes and Clinical Response in Patients with Moderate-to-severe Plaque Psoriasis Treated with Tonsillectomy: A Randomized Controlled Trial

被引:28
|
作者
Thorleifsdottir, Ragna Hlin [1 ,2 ]
Sigurdardottir, Sigrun Laufey [3 ]
Sigurgeirsson, Bardur [1 ]
Olafsson, Jon Hjaltalin [1 ]
Sigurdsson, Martin Ingi [4 ]
Petersen, Hannes [5 ]
Gudjonsson, Johann Eli [6 ]
Johnston, Andrew [6 ]
Valdimarsson, Helgi [3 ]
机构
[1] Univ Iceland, Dermatol Sect, Fac Med, Reykjavik, Iceland
[2] Uppsala Univ, Dept Med Sci, Dermatol, Uppsala, Sweden
[3] Landspitali Natl Univ Hosp Iceland, Dept Immunol, Reykjavik, Iceland
[4] Landspitali Natl Univ Hosp Iceland, Dept Anesthesiol & Crit Care, Reykjavik, Iceland
[5] Landspitali Natl Univ Hosp Iceland, Dept Otolaryngol Head & Neck Surg, Reykjavik, Iceland
[6] Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI USA
关键词
chronic plaque psoriasis; streptococcal throat infection; tonsillectomy; health-related quality of life; Psoriasis Disability Index; Psoriasis Life Stress Inventory; QUALITY-OF-LIFE; STREPTOCOCCAL THROAT INFECTIONS; RECALCITRANT PSORIASIS; GUTTATE PSORIASIS; PERIPHERAL-BLOOD; VULGARIS; CELLS; PATHOGENESIS; IMPROVEMENT; ONSET;
D O I
10.2340/00015555-2562
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Psoriasis is a chronic inflammatory skin disease with profound effects on patients' health-related quality of life (HRQoL). Twenty-nine patients with plaque psoriasis and a history of streptococcal-associated psoriasis exacerbations were randomly assigned to tonsillectomy (n = 15) or control (n = 14) groups and followed for 24 months. Patients were evaluated with the Psoriasis Disability Index, Psoriasis Life Stress Inventory and Psoriasis Area and Severity Index. HRQoL and psoriasis-related stress improved significantly in the tonsillectomy group compared with the control group (p = 0.037 and p = 0.002, respectively), with a mean 50% improvement in HRQoL and a mean 59% improvement in psoriasis-induced stress. Clinical improvement correlated significantly with improved HRQoL (r = 0.297, p = 0.008) and psoriasis-related stress (r = 0.310, p = 0.005). Of the tonsillectomized patients, 87% concluded that the procedure was worthwhile. Tonsillectomy may improve quality of life for selected patients with plaque psoriasis.
引用
收藏
页码:340 / 345
页数:6
相关论文
共 50 条
  • [21] Physician- and Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis Treated With Apremilast During Routine Dermatology Care in Germany
    Reich, Kristian
    Fritzlar, Stefanie
    Korge, Bernhard
    Manasterski, Maria
    Schwichtenberg, Uwe
    Morys, Stephan
    Lorenz-Baath, Katrin
    Roemmler-Zehrer, Josefine
    Gomez, Natalie Nunez
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 21 - 21
  • [22] Treatment with etanercept improves patient-reported outcomes in patients with moderate to severe psoriasis
    Gottlieb, A
    Woolley, JM
    Lalla, D
    Jahreis, A
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P201 - P201
  • [23] Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice
    Duffin, K. Callis
    Yeung, H.
    Takeshita, J.
    Krueger, G. G.
    Robertson, A. D.
    Troxel, A. B.
    Shin, D. B.
    Van Voorhees, A. S.
    Gelfand, J. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (03) : 672 - 680
  • [24] Impact of sustained robust response on patient-reported outcomes for adalimumab-treated patients with moderate to severe psoriasis: Subanalysis of REVEAL
    Strober, Bruce
    Sundaram, Murali
    Bao, Yanjun
    Gu, Yihua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB194 - AB194
  • [25] Improvements in patient-reported outcomes (PROs) among moderate to severe plaque psoriasis patients treated with brodalumab: Results from AMAGINE-1
    Strober, Bruce
    Gordon, Kenneth
    Augustin, Matthias
    Viswanathan, Hema
    Klekotka, Paul
    Milmont, Cassandra
    Kricorian, Gregory
    Harrison, David
    Pinto, Lionel
    Nirula, Ajay
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB256 - AB256
  • [26] Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO)
    Travaglini, Massimo
    Maul, Julia -Tatjana
    Kors, Christian
    Zaheri, Shirin
    Gerwien, Jens
    Mueller, Michaela
    Brnabic, Alan
    Sabatino, Silvia
    Schuster, Christopher
    Tsai, Tsen-Fang
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2023, 16 : 2971 - 2983
  • [27] Impact of efalizumab on patient-reported outcomes in patients with moderate to severe plaque psoriasis: Pooled results from three randomized phase III trials
    Menter, A
    Hamilton, T
    Caro, I
    Chen-Rundle, A
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P156 - P156
  • [28] Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT)
    Paul, C.
    Puig, L.
    Kragballe, K.
    Luger, T.
    Lambert, J.
    Chimenti, S.
    Girolomoni, G.
    Nicolas, J. -F.
    Rizova, E.
    Lavie, F.
    Mistry, S.
    Bergmans, P.
    Barker, J.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (02) : 425 - 434
  • [29] MEASUREMENT PROPERTIES OF THE PATIENT-REPORTED PSORIASIS SYMPTOM INVENTORY DAILY DIARY IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
    Viswanathan, H. N.
    Mutebi, A.
    Milmont, C. E.
    Gordon, K.
    Wilson, H.
    Zhang, H.
    Klekotka, P.
    Revicki, D. A.
    Augustin, M.
    Kricorian, G.
    Nirula, A.
    Strober, B.
    VALUE IN HEALTH, 2015, 18 (03) : A183 - A183
  • [30] Patient-reported symptoms and signs in patients with moderate-severe plaque psoriasis treated with guselkumab or adalimumab: Results from VOYAGE 1, a phase III clinical trial
    Blauvelt, Andrew
    Papp, Kim
    Griffiths, Christopher E. M.
    Han, Chenglong
    Randazzo, Bruce
    Wasfi, Yasmine
    Li, Shu
    Kimball, Alexa B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB191 - AB191